



PERFLUOROOCTANOIC ACID (PFOA)
AND PERFLUOROOCTANESULFONIC
ACID (PFOS)

VOLUME 135

This publication represents the views and expert opinions of an IARC Working Group on the Identification of Carcinogenic Hazards to Humans, which met in Lyon, France, 7–14 November 2023

LYON, FRANCE - 2025

IARC MONOGRAPHS
ON THE IDENTIFICATION
OF CARCINOGENIC HAZARDS
TO HUMANS

ANNEX 5. SUPPLEMENTARY MATERIAL FOR SECTIONS 4.1 AND 4.2, MECHANISTIC EVIDENCE

These supplementary online-only tables are available from: <https://publications.iarc.who.int/636>.

Please report any errors to imo@iarc.who.int.

The following tables were produced in draft form by the Working Group and were subsequently fact-checked but not edited:

Table S4.1	Calculations to derive dissociation constants, by the Working Group
Table S4.23	End-points relevant to modulation of receptor-mediated effects in humans exposed to PFOA or PFOS
Table S4.24	End-points relevant to modulation of receptor-mediated effects in human cells in vitro exposed to PFOA or PFOS
Table S4.25	End-points relevant to modulation of receptor-mediated effects in experimental systems in vivo exposed to PFOA or PFOS
Table S4.26	End-points relevant to modulation of receptor-mediated effects (endocrine) in experimental systems in vivo exposed to PFOA and PFOS